Baidu
map

Neurology:综合多研究,MRI诊断局灶性皮质发育不良难治性癫痫术后优良预后率达70%

2022-01-16 Naomi MedSci原创

有研究者对现有文献进行了系统的回顾和荟萃分析,以确定MRI检测的FCD手术后癫痫发作预后良好的比率和预测因素。 70%的具有FCD MRI特征的难治性癫痫患者在切除手术后可获得良好的癫痫发作结果。

      局灶性皮质发育不良(FCD)包括一系列皮质发育的局灶性畸形,特征是皮质层叠紊乱,伴或不伴有异常细胞类型。虽然FCD的确诊依赖于组织病理学(在某些情况下,还包括遗传学),但实际上诊断始于磁共振成像(MRI),作为耐药癫痫患者术前评估的一部分。FCD的特征性MRI特征包括局灶性皮质增厚、脑回和脑沟模式异常、皱褶大小改变、皮质和皮质下信号异常、灰白质交界处模糊,以及从皮质延伸到脑室的漏斗状高T2/FLAIR信号(跨地幔征)。值得注意的是,这些特征可能是微妙或完全无法识别,即使经过专家审查,21-58%的FCD病变在MRI上也无法识别。

      FCD是耐药癫痫的一个重要原因,也是癫痫手术的第三个最常见的适应症,仅次于海马硬化症和肿瘤。然而,与其他病理相比,FCD被报道与较差的手术后癫痫结果有关。在接受FCD相关耐药癫痫手术的患者中,那些变得“无致残性癫痫发作”(Engel I级结果)的比例差别很大。从8.3%到86.4%不等。对这类研究的荟萃分析发现,Engel I级预后的总体比率为55.8%±16.2%。

       然而,FCD手术系列通常建立在FCD的组织病理学诊断的基础上,因此包括MRI检测到的FCD患者和MRI未检测到的FCD患者(MRI阴性病例)的混合队列。虽然基于组织学的术后预测可能是有用的,但在常规的临床工作流程中,手术患者的选择是基于术前的结果,包括MRI。关于接受MRI检测的FCD手术患者癫痫发作结果的研究缺乏全面的评估和分析,这一努力可以为临床医生提供关键数据,用于对正在接受癫痫手术的MRI检测到的FCD患者进行常规咨询。为了解决这一认识差距,有研究者对现有文献进行了系统的回顾和荟萃分析,以确定MRI检测的FCD手术后癫痫发作预后良好的比率和预测因素。拟解决问题包括以下几点:

(Ⅰ)确定MRI检测到的FCD相关的难治性癫痫手术后预后良好的总体比率(主要目标);

(Ⅱ)确定此类手术后良好发作结果的预测因素;

(Ⅲ)确定研究质量对报告的术后预后良好的任何影响。

      研究者根据PRISMA指南设计了我们的研究方案,并在Prospero注册了该方案。检索MEDLINE、EMBASE和科学网,查找≥检测到的耐药癫痫切除术后12个月患者的随访研究。随机效应荟萃分析用于计算获得良好结果(定义为Engel I级、ILAE 1-2级或“无癫痫”状态)的患者的比例。用Meta回归分析异质性的来源。

  • 搜索发现了3745条参考文献。其中,35项研究(共1353名患者)包括在内。
  • 大多数研究(89%)在术后24个月跟踪观察患者术后优良预后率为70%(95%CI:64~75)。
  • 研究间有很高的异质性。
  • 良好的预后与病变完全切除[风险比RR=2.42(95%CI:1.55~3.76,p<0.001)]和病变部位在颞叶[RR=1.38(95%CI:1.07~1.79,p=0.013)]有关,但与病变范围、颅内脑电图使用或FCD组织学类型无关。
  • 同一研究中包括的FCD组织类型的数量占观察到的异质性的7.6%。

      70%的具有FCD MRI特征的难治性癫痫患者在切除手术后可获得良好的癫痫发作结果。该发现可纳入常规术前咨询,并强调在安全和可行的情况下完全切除MRI检测到的FCD的重要性。

文献来源:Willard, Anna et al. “Seizure Outcome After Surgery for MRI-Diagnosed Focal Cortical Dysplasia: A Systematic Review and Meta-analysis.” Neurology, 10.1212/WNL.0000000000013066. 10 Dec. 2021, doi:10.1212/WNL.0000000000013066

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009709, encodeId=0ac22009e099d, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Sep 19 07:56:40 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001691, encodeId=33302001691e9, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 03 17:56:40 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188195, encodeId=2c0b118819581, content=学了,非常棒的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8fd6479443, createdName=ms7000000113042242, createdTime=Wed Jan 26 04:05:25 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347598, encodeId=7c15134e59852, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568017, encodeId=1701156801e87, content=<a href='/topic/show?id=7a833e94079' target=_blank style='color:#2F92EE;'>#发育不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37940, encryptionId=7a833e94079, topicName=发育不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30b515313716, createdName=villahu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009709, encodeId=0ac22009e099d, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Sep 19 07:56:40 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001691, encodeId=33302001691e9, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 03 17:56:40 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188195, encodeId=2c0b118819581, content=学了,非常棒的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8fd6479443, createdName=ms7000000113042242, createdTime=Wed Jan 26 04:05:25 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347598, encodeId=7c15134e59852, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568017, encodeId=1701156801e87, content=<a href='/topic/show?id=7a833e94079' target=_blank style='color:#2F92EE;'>#发育不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37940, encryptionId=7a833e94079, topicName=发育不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30b515313716, createdName=villahu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-12-03 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009709, encodeId=0ac22009e099d, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Sep 19 07:56:40 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001691, encodeId=33302001691e9, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 03 17:56:40 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188195, encodeId=2c0b118819581, content=学了,非常棒的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8fd6479443, createdName=ms7000000113042242, createdTime=Wed Jan 26 04:05:25 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347598, encodeId=7c15134e59852, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568017, encodeId=1701156801e87, content=<a href='/topic/show?id=7a833e94079' target=_blank style='color:#2F92EE;'>#发育不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37940, encryptionId=7a833e94079, topicName=发育不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30b515313716, createdName=villahu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-26 ms7000000113042242

    学了,非常棒的文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2009709, encodeId=0ac22009e099d, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Sep 19 07:56:40 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001691, encodeId=33302001691e9, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 03 17:56:40 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188195, encodeId=2c0b118819581, content=学了,非常棒的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8fd6479443, createdName=ms7000000113042242, createdTime=Wed Jan 26 04:05:25 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347598, encodeId=7c15134e59852, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568017, encodeId=1701156801e87, content=<a href='/topic/show?id=7a833e94079' target=_blank style='color:#2F92EE;'>#发育不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37940, encryptionId=7a833e94079, topicName=发育不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30b515313716, createdName=villahu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 neurowu
  5. [GetPortalCommentsPageByObjectIdResponse(id=2009709, encodeId=0ac22009e099d, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Sep 19 07:56:40 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001691, encodeId=33302001691e9, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 03 17:56:40 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188195, encodeId=2c0b118819581, content=学了,非常棒的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8fd6479443, createdName=ms7000000113042242, createdTime=Wed Jan 26 04:05:25 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347598, encodeId=7c15134e59852, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568017, encodeId=1701156801e87, content=<a href='/topic/show?id=7a833e94079' target=_blank style='color:#2F92EE;'>#发育不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37940, encryptionId=7a833e94079, topicName=发育不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30b515313716, createdName=villahu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-01-18 freve
  6. [GetPortalCommentsPageByObjectIdResponse(id=2009709, encodeId=0ac22009e099d, content=<a href='/topic/show?id=c7804e581bc' target=_blank style='color:#2F92EE;'>#局灶性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47581, encryptionId=c7804e581bc, topicName=局灶性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Mon Sep 19 07:56:40 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001691, encodeId=33302001691e9, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 03 17:56:40 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188195, encodeId=2c0b118819581, content=学了,非常棒的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8fd6479443, createdName=ms7000000113042242, createdTime=Wed Jan 26 04:05:25 CST 2022, time=2022-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347598, encodeId=7c15134e59852, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528833, encodeId=675b15288338a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568017, encodeId=1701156801e87, content=<a href='/topic/show?id=7a833e94079' target=_blank style='color:#2F92EE;'>#发育不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37940, encryptionId=7a833e94079, topicName=发育不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30b515313716, createdName=villahu, createdTime=Tue Jan 18 09:56:40 CST 2022, time=2022-01-18, status=1, ipAttribution=)]

相关资讯

Brain:癫痫动不动就耐药?使用MRI或可对亚型进行异质性分析

对于70%的癫痫患者来说,药物可以控制癫痫发作。

拓展阅读

Neurology:伴沟底发育不良的癫痫双侧结构网络异常

研究证明了双边分布的、特定的白质网络在BOSD中易受干扰的证据。纤维束异常的程度部分与癫痫发作活动有关,但其他因素,如遗传背景和治疗或环境的影响并未被排除在外。

氯巴占治疗难治性癫痫专家共识(2022)

北京协和医院罕见病多学科协作组 · 2022-08-22

2016 婴幼儿难治性癫痫患者生酮饮食指南

国外儿科相关医学专家组(统称) · 2016-07-17

Baidu
map
Baidu
map
Baidu
map